ClinicalTrials.gg
TerminatedNCT05125068Updated Mar 26, 2024

Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)

A Phase 2 interventional study of AT-1501 in IgA Nephropathy and IgAN, sponsored by Eledon Pharmaceuticals. Terminated at 26 sites in 10 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-03-26.

Sponsored by Eledon Pharmaceuticals · Phase 2, Interventional, and Treatment

Why this study was terminated
An administrative decision was made to terminate the AT-1501-N205 study. This voluntary business-related decision was not related to the safety of tegoprubart (AT-1501). Available safety data demonstrated tegoprubart to be safe and well tolerated.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Glomerulonephritis, IGA with a site in Malaysia — 6 open to participants now, 10 under way, 8 of them phase 3. Glomerulonephritis, IGA · Malaysia.

Enrollment
18th of 19
24 · median 220
Started
2022
with 3 others
Phase 2
8 of 20
2 open now
Registered
9th of 20
by date
Lead sponsor
1 of 20
Eledon Pharmaceuticals

Among the 20 studies in Glomerulonephritis, IGA with a site in Malaysia, this one is the 18th largest by enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2022, is one of 8 in phase 2, and was the 9th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

6 of the 20 studies in Glomerulonephritis, IGA with a site in Malaysia are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Malaysia have not opened yet or have stopped. Only those recruiting at a site in Malaysia →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Glomerulonephritis, IGA with a site in Malaysia, or all of them as a file.
02

Study summary

This is a phase 2a, multicenter, open-label study designed to evaluate the safety and efficacy of AT-1501 in patients with biopsy proven IgAN and at least 0.75 g/24 hours of protein in their urine at the time of screening.

Read the detailed description

Phase 2a, multicenter, open-label study designed to evaluate the safety and efficacy of AT-1501 in patients with biopsy proven IgAN and at least 0.75 g/24 hours of protein in their urine at the time of Screening. Up to 42 eligible patients will receive one of 2 doses of AT-1501. All patients are scheduled to receive AT-1501 by intravenous infusion every 3 weeks for approximately 2 years.

03

Conditions studied

  • IgA Nephropathy
  • IgAN

Keywords

  • IgA Nephropathy
  • IgAN
  • AT-1501
  • CD40L
  • Monoclonal antibody
  • Proteinuria
  • eGFR
  • UPCR
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥ 18 years of age
  2. proven IgAN
  3. Urine protein ≥ 0.75g/24 hours at Screening despite optimization with ACE inhibitors or angiotensin receptor blockers (ARB)
  4. ≥ 45 mL/min per 1.73 m2 or eGFR \< 45 mL/min per 1.73 m2 and ≥ 30 mL/min per 1.73 m2 with a kidney biopsy within 2 years of Screening showing \< 50% tubulointerstitial fibrosis
  5. Agree to comply with requirements during and for 90 days after study completion.

Exclusion criteria

Exclusion Criteria:

  1. Any secondary IgAN as defined by the investigator
  2. Patients who have undergone a kidney transplant
  3. Any history of kidney disease other than IgAN
  4. Any history of diabetes (Type 1 or Type 2)
  5. Seated blood pressure > 140 mmHg (systolic) or > 90 mmHg (diastolic) at the Screening Visit. Patients must be on a stable dose and regimen of an ACE inhibitor or ARB for at least 90 days
  6. Pregnancy or breastfeeding.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Arm A

    AT-1501 10mg/kg Arm A will receive 10 mg/kg of AT-1501 every 3 weeks for up to 93 weeks for a total of 32 infusions.

    Drug: AT-1501

  • Experimental
    Arm B

    AT-1501 5mg/kg Arm B will receive 5 mg/kg of AT-1501 every 3 weeks for up to 93 weeks for a total of 32 infusions

    Drug: AT-1501

Interventions

  • AT-1501 monoclonal antibody targeting CD40L given as an IV infusion

06

What researchers measure

Primary outcomes

  1. Efficacy - change in participants UPCR

    The change in 24-hour urine protein to creatinine ratio (UPCR) from baseline to 24 weeks

    Time frame: Up to 24 weeks

  2. Safety- Number of participants with treatment related adverse events

    Incidence of serious adverse events (SAEs), treatment-emergent adverse events (TEAEs), and AEs of special interest (AEoSI)

    Time frame: Through study completion, an average of 100 weeks

Secondary outcomes

  1. Change in eGFR slope

    The change in eGFR slope from baseline to 96 weeks

    Time frame: Baseline- 96 weeks

  2. Change in urine protein excretion (mg/mg)

    The change in urine protein excretion over time

    Time frame: Up to 96 weeks

  3. Development of Anti drug Antibodies (ADAs)

    The percentage of participants who develop ADAs

    Time frame: Up to 96 weeks

Other outcomes

  1. Exploratory- Change in baseline serum biomarkers

    The change in serum biomarkers from baseline to completion of study

    Time frame: Through study completion, an average of 100 weeks

07

Study locations

26 sites
  • Liverpool Hospital
    Liverpool, South Wales NSW 2170, Australia
  • Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • Western Health
    St Albans, Victoria, Australia
  • University Hospital Centre Sisters of Charity
    Zagreb, Croatia
  • University Hospital Dubrava Zagreb
    Zagreb, Croatia
  • University Malaya Medical Centre (UMMC)
    Kuala Lumpur, Kuala Lumpur WP 59100, Malaysia
  • Hospital Tengku Ampuan Afzan (HTAA)
    Kuantan, Pahang 25100, Malaysia
  • Hospital Queen Elizabeth
    Kota Kinabalu, Sabah, Malaysia
  • Hospital Serdang
    Kajang,, Selangor 43000, Malaysia
  • Hospital Kajang
    Kajang, Selangor 43000, Malaysia
  • Waikato Hospital
    Hamilton, 3204, New Zealand
  • Hawke's Bay Hospital
    Hastings, 4120, New Zealand
  • University of Santo Tomas Hospital
    Sampaloc, Manila, Philippines
  • Medical University of Bialystok UI
    Białystok, Poland
  • Specjalistyczne Centrum Medyczne, SCM Spółka
    Krakow, Poland
  • Hospital de Sagunto
    Sagunto, Valencia, Spain
  • Hospital Clinico San Carlos
    Madrid, Spain
  • Hospital Virgen de la Macarena
    Sevilla, Spain
  • Hospital Universitario Miguel Servet
    Zaragoza, Spain
  • National Hospital of Sri Lanka
    Colombo, 01000, Sri Lanka
  • Sri Jayawardanepura General Hospital
    Nugegoda, 10250, Sri Lanka
  • Prince of Songkla University
    Dusit, Bangkok, Thailand
  • Chulalongkorn University
    Pathum Wan, Bangkok 10330, Thailand
  • Phramongkutklao Hospital
    Bangkok, Thailand
  • Chiang Mai University
    Chiang Mai, Thailand
  • Kings College Hospital
    Camberwell, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Jul 2023, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2021
First posted
Nov 18, 2021
StartActual
Mar 21, 2022
Primary completionActual
Jul 31, 2023
CompletionActual
Jul 31, 2023
Last update
Mar 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05125068
Lead sponsor
Eledon Pharmaceuticals
Responsible party
Sponsor
First posted
Nov 18, 2021
Start date
Mar 21, 2022
Primary completion
Jul 31, 2023
Completion
Jul 31, 2023
Last update
Mar 26, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tegoprubart

Start the discussion